SPOTLIGHT: Acorda announces added trial
Acorda Therapeutics has announced an additional late-stage trial of Fampridine-SR for multiple sclerosis. Researchers are working with the FDA to design a new Phase III study of the same or shorter duration as the recently completed trial. That study demonstrated that volunteers taking the drug experienced significantly improved walking speed. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
